Skip Header

You are using a version of browser that may not display all the features of this website. Please consider upgrading your browser.

A comparative analysis of the aggregation behavior of amyloid-beta peptide variants.

Vandersteen A., Hubin E., Sarroukh R., De Baets G., Schymkowitz J., Rousseau F., Subramaniam V., Raussens V., Wenschuh H., Wildemann D., Broersen K.

Aggregated forms of the amyloid-β peptide are hypothesized to act as the prime toxic agents in Alzheimer disease (AD). The in vivo amyloid-β peptide pool consists of both C- and N-terminally truncated or mutated peptides, and the composition thereof significantly determines AD risk. Other variations, such as biotinylation, are introduced as molecular tools to aid the understanding of disease mechanisms. Since these modifications have the potential to alter key aggregation properties of the amyloid-β peptide, we present a comparative study of the aggregation of a substantial set of the most common in vivo identified and in vitro produced amyloid-β peptides.

FEBS Lett. 586:4088-4093(2012) [PubMed] [Europe PMC]